Following Oncopeptides AB?
Get the free weekly contract digest
The latest new contracts, like Oncopeptides AB’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Oncopeptides partners with Veld and Slavpharma to distribute Pepaxti in Africa and Eurasia
Sep 04, 2024•almost 2 years ago
Contract Type
partnership
Biotechnology
Description
Oncopeptides AB has announced a partnership with Veld Pharmaceuticals GmbH and Slavpharma GmbH to commercialize its flagship drug Pepaxti (melphalan flufenamide) in Africa and Eurasia for the treatment of patients with multiple myeloma.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months